To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

March 11, 2019

Today's Rundown

Featured Story

Axovant trumpets new clinical data after gene therapy pivot

Axovant has a pair of clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s disease—and the initial data look encouraging.

Top Stories

Snipr raises $50M to use CRISPR to modulate the microbiome

Snipr Biome has raised $50 million to take CRISPR-based microbiome drugs into clinical trials. The Danish biotech is using CRISPR/Cas to selectively target and kill bacteria with specific DNA sequences. 

Celgene's MS drug ozanimod gets EU filing, with FDA submission to follow

The submission comes a year after Celgene received an embarrassing refuse-to-file letter for ozanimod from the FDA after the agency determined that the nonclinical and clinical pharmacology information provided were insufficient.

[Sponsored] INCORPORATING THE PATIENT VOICE TO IMPROVE ULCERATIVE COLITIS RECRUITMENT

Strengthen Your Protocol With Patient Insights. See how Covance helps sponsors reduce patient burden to increase participation and improve patient retention.

Stemline licenses RET inhibitor from U.K. cancer group

Stemline Therapeutics has licensed the global rights to a preclinical RET inhibitor. The drug, SL-1001, was designed to improve outcomes in RET-dependent tumors by selectively hitting the target.

IBM uses machine learning to detect early Alzheimer’s in blood samples

A buildup of the protein amyloid-beta in spinal fluid can predict Alzheimer's long before symptoms appear, but it's difficult to detect. IBM researchers have identified four proteins that can be found in blood and can predict amyloid-beta buildup with up to 77% accuracy.

Resources

[Whitepaper] The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing

The Right Partner Can Improve Flexibility and Mitigate Risks from Forecast Inaccuracy in Biomanufacturing.

[Whitepaper] How changes in drug substance processes can affect formulation

Download this whitepaper to learn more.

[Research] Maximize Pharma Marketing ROI with Digital HCP Engagement

Which HCP Touchpoints and channels are yielding the best results in today’s digital world?

[Whitepaper] Cell-Based Cancer Immunotherapies: Commercial Risk, Curative Reward

White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each.

[Whitepaper] Better Market Intelligence With Smart Search

It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies.

[Whitepaper] Accelerate Time To Market Working With Industry Specialist MSP

With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market.

[Survey] Veeva 2019 Unified Clinical Operations Survey

Share your thoughts on the life sciences industry's progress in improving study execution.

[eBook] 2018 Weekly Compendium

The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry.

Events